<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332109</url>
  </required_header>
  <id_info>
    <org_study_id>ODM5FDE-PMCF-DE-2015-01</org_study_id>
    <nct_id>NCT02332109</nct_id>
  </id_info>
  <brief_title>ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy</brief_title>
  <official_title>ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRB Chemedica AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TRB Chemedica AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical observation to confirm the clinical safety and efficacy of ODM 5 in the treatment of
      corneal edema caused by Fuchs' endothelial dystrophy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a Fuchs' endothelial dystrophy-induced corneal edema and an ODM 5 therapy
      recommendation prior to their inclusion will be observed in normal practice setting in this
      post-market clinical follow-up study. In this indication, the use of ODM 5 should extract the
      fluid excess in the cornea away by an osmotic effect, enabling the cornea to temporarily
      regain a normal state of hydration. As a consequence, the patient's visual acuity, contrast
      perception, corneal thickness and ocular complaints/symptoms should improve. The hyaluronan
      in ODM 5 helps to protect and heal the cornea in case of irritation and thus, enables the
      cornea to regain a normal state of hydration and participates in improving the quality of
      vision.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity (both eyes)</measure>
    <time_frame>Day 56</time_frame>
    <description>Measurement of uncorrected and best corrected visual acuity (both eyes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal thickness</measure>
    <time_frame>Day 0, day 28 and day 56</time_frame>
    <description>Measurement of central corneal thickness (both eyes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity (both eyes)</measure>
    <time_frame>Day 0 and day 28</time_frame>
    <description>Measurement of uncorrected and best corrected visual acuity (both eyes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast perception (Measurement of contrast values (both eyes))</measure>
    <time_frame>Day 0, day 28 and day 56</time_frame>
    <description>Measurement of contrast values (both eyes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective ocular complaints and symptoms (11-point Likert scale)</measure>
    <time_frame>Day 0, day 28 and day 56</time_frame>
    <description>The following ocular complaints or symptoms will be evaluated on an 11-point Likert scale ranging from '0' (no complaints) to '10' (maximum complaints):
glare sensitivity
burning
foreign body sensation
halos
pruritus
blurred vision
redness
pain
tingling
stitching
dryness
watering eyes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameter (Adverse events)</measure>
    <time_frame>Day 0, day 28 and day 56</time_frame>
    <description>Adverse events judged to be unexpected and (possibly) related to ODM 5 will be documented</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">29</enrollment>
  <condition>Fuchs' Endothelial Dystrophy</condition>
  <condition>Corneal Edema</condition>
  <arm_group>
    <arm_group_label>ODM 5-group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ODM 5</intervention_name>
    <description>ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.</description>
    <arm_group_label>ODM 5-group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a Fuchs endothelial dystrophy-induced corneal edema and an ODM 5 therapy
        recommendation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of corneal oedema caused by Fuchs' endothelial dystrophy

          -  Existing ODM 5 recommendation prior to inclusion

        Exclusion Criteria:

          -  Contact lens wear

          -  Hypersensitivity to one of the ODM 5 components

          -  Appointment for eye surgery within 8 weeks after date of inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Augenklinik</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Thomas Kaercher</name>
      <address>
        <city>Heidelberg</city>
        <zip>69121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg A.ö.R., Universitätsaugenklinik</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenklinik der Ludwig-Maximilians-Universität (LMU), Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>January 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fuchs endothelial dystrophy</keyword>
  <keyword>oedema</keyword>
  <keyword>sodium chloride</keyword>
  <keyword>hyaluronan</keyword>
  <keyword>sodium hyaluronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
    <mesh_term>Corneal Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

